Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)
Sponsored by Leadiant Biosciences Ltd.
About this trial
Last updated 3 years ago
Study ID
CDCA-STUK-15-001
Status
Completed
Type
Observational
Placebo
No
Accepting
All
All
Trial Timing
Ended 10 years ago
What is this trial about?
Retrospective study of CTX patients to investigate the safety and clinical efficacy of
Chenodeoxycholic Acid
What are the participation requirements?
Inclusion Criteria
Diagnosis of CTX Received treatment with CDCA Age between 2 and 75 years Having at least one cholestanol level and/or urinary bile alcohol level no more than 3 months prior to treatment with CDCA and one cholestanol level and/or urinary bile alcohol level post-treatment within 2 years from the beginning of therapy with CDCA
Exclusion Criteria
-